Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises & Experts

通过生态系统、企业增加 IDeA 州生物医学创业精神

• 批准号: 10761120
• 负责人: Julius N. Korley
• 金额: $ 27.36万
• 依托单位: INSITEHUB LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-21 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10761120
• 关键词: Address; Area; Award; Basic Science; Biological Models; Biomedical Research; Biotechnology; Businesses; Cessation of life; Chemistry; Critical Pathways; Data; Delaware; Development; Disclosure; Ecosystem; Education; Educational Curriculum; Engineering; Ensure; Entrepreneurship; Evaluation; Exposure to; Failure; Funding; Goals; Institution; Intervention; Interview; Knowledge; Learning; Legal patent; Licensing; Marketing; Measures; Medical; Medical Technology; Mentors; Methodology; Modeling; Monitor; National Institute of General Medical Sciences; Participant; Pathway interactions; Patients; Performance; Pharmacologic Substance; Phase; Phase Transition; Price; Private Sector; Process; Program Evaluation; Readiness; Request for Proposals; Resources; Science; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Technology; Technology Transfer; Testing; Training; Translating; Universities; Voice; Work; cohort; commercialization; experience; ideation; improved; innovation; innovative technologies; insight; invention; new technology; online course; outreach; product development; programs; prototype; research study; success; technology development; trend; validation studies

Summary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer interviews regarding challenges to the commercialization of biomedical innovations, there are 3 main barriers to translating basic science products that benefit patients, 1) gap in funding between basic research and validation studies required for early-stage development, 2) lack of knowledge and understanding by innovators about how technologies are brought to market, and 3) lack of access to sufficient technology development and commercialization resources. The creation of the IDeA state program is clear evidence of the need for resources not only to cultivate biomedical research but to spur on commercialization of the new technology created. Correctly identifying deficiencies in the commercialization pathway and preemptively providing corrective measures will create better entrepreneurs and increase the likelihood of commercialization. Our team will develop a rigorous and engaging online curriculum to support the goals and bridge the gap of sufficient training and knowledge for innovators through a high-availability, scalable, on-demand platform. The platform will help both new and experienced innovators to focus on areas of need and provide direct learning interventions from ideation, to market assessment, and go- to-market strategies and will allow for live mentoring and coaching interactions online to support and supplement the curriculum. Data and advanced insights will be analyzed for both the overall program and the learning process that will yield trends as to the correlation between innovators who are deemed successful and the parts of the program leveraged most, allowing us to continuously improve the program. This will result in a more robust education, an increase in the number of biomedical entrepreneurs, an increase in the number of biomedical startups developing market-driven technologies applying for SBIR/STTR and accessing existing ecosystem resources, and increased connectivity between innovative technologies and other enterprises and experts. The specific aims align participants and establish the DE iRED organization with deliverables that include team governance criteria and processes, and innovator roadmaps for Delaware, Northeast, and wider region/IDeA states.They also include the launch of final program and outreach campaigns (local > northeast) and programming using data obtained through pilot activities, testing the revenue model and pricing for sustainability as well as increased reach of the launch outreach campaign to the Northeast and national venue.

概括 拟议的 DE iRED 计划由大学和私营部门合作组成，旨在提供 综合计划将吸引和支持处于技术早期阶段的生物医学创新者 通过解决招揽和确定的启动过程中的关键瓶颈来实现商业化 根据 DRIVEN 的客户之声采访，了解 DRIVEN 加速器中心面临的挑战。 生物医学创新的商业化，基础科学产品的翻译存在3个主要障碍 使患者受益，1）早期所需的基础研究和验证研究之间的资金差距 发展，2）创新者缺乏关于如何将技术应用到市场的知识和理解 市场，3) 缺乏足够的技术开发和商业化资源。 IDeA 国家计划的创建清楚地证明了不仅需要资源来培育生物医学 研究，但要促进所创造的新技术的商业化，正确识别缺陷。 商业化路径和先发制人的纠正措施将创造更好的企业家 并增加商业化的可能性。 通过课程来支持目标并弥合创新者在充分培训和知识方面的差距 高可用性、可扩展、按需平台将帮助新的和经验丰富的创新者。 专注于需要的领域，并提供从构思到市场评估和实施的直接学习干预 市场策略，并将允许在线实时指导和指导互动，以支持和补充 将对整个课程和学习的数据和高级见解进行分析。 该过程将产生关于被认为成功的创新者与零件之间相关性的趋势 的程序利用最多，使我们能够不断改进该程序，这将导致更强大的程序。 教育、生物医药企业家人数增加、生物医药企业家人数增加 开发市场驱动技术、申请 SBIR/STTR 并接入现有生态系统的初创公司 资源，并增强创新技术与其他企业和专家之间的联系。 具体目标使参与者保持一致并建立 DE iRED 组织，其可交付成果包括 特拉华州、东北部及更广泛地区的团队治理标准和流程以及创新者路线图 地区/IDeA 州。还包括启动最终计划和外展活动（当地 > 东北部） 并使用通过试点活动获得的数据进行编程，测试收入模型和定价 可持续性以及扩大启动推广活动在东北部和全国范围内的影响范围。